AltPep, a Seattle-based biotech startup tackling amyloid protein disorders, has raised $23.1 million in a Series A funding round.
The venture spun out the...
Flexibly designed nanomaterials can trigger specific immune responses and might offer promising alternatives to traditional immunosuppressive therapies, cancer immunotherapies and vaccine formulations. ...
Startup of the week: Kaholo
Cyabra exposes vaccine disinformation
BlueGreen brings freshwater hope to Florida
$167B marks SPACtacular year for IPOs
Highcon: The complete package
Nanomedic: The...
Chemicals used for vaping break down zipper-like junctions between cells in the gut, leading to chronic inflammation and potential for other health concerns...
January 6th, 2021 by NRDC
Originally published on the NRDC Expert Blog.By Emily Davis & John Walke & Vijay Limaye
In defiance of science and the law,...
December 29, 2020 ViviGen Cellular Bone Matrix, is the first cellular allograft to recover and protect viable, lineage-committed bone cells, supports outcomes that...
Demographic information from clinical trialsClinical trials for the Moderna vaccine included people from the following racial and ethnic categories:
79.4% White
20% Hispanic/Latino
9.7% African American
4.7%...
